Home・Stock List・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Closed

SectorHealthcare

18.1 -1.79

Buy Sell

Overview

Share price change

24h

Current

Min

17.86

Max

18.23

Key metrics
By Trading Economics
Income	-4.9M 326M
Sales	-330M 401M
P/E Sector Avg	42.919 57.002
EPS	0.42
Profit margin	81.263
Employees	835
EBITDA	-345M 30M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+25.03% upside

Dividends
By Acuity
Next Earnings	2 Nov 2026

Market Stats
By TradingEconomics
Market Cap	138M 1.8B
Previous open	19.89
Previous close	18.1

News Sentiment

By Acuity

80%

20%

315 / 340 Healthcare

Sarepta Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Aug 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13 Aug 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12 Aug 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11 Aug 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10 Aug 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7 Aug 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

6 Aug 2026, 20:03 UTC

Social Media

News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

5 Aug 2026, 23:11 UTC

News

Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

4 Aug 2026, 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

3 Aug 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

30 Jul 2026, 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

29 Jul 2026, 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

28 Jul 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

27 Jul 2026, 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

21 Jul 2026, 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Peer Comparison

Price change

Sarepta Therapeutics Inc Forecast

Price Target

By TipRanks

25.03% upside

12 Months Forecast

Average 22.63 USD 25.03%

High 38 USD

Low 5 USD

Based on 17 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

17 ratings

Buy

Hold

Sell

Based on 17 analysts giving stock ratings to Sarepta Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

315 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.